The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease (NCT04122469)
🩺 Plain-English Summary (8th-Grade Level)
Systemic therapy is the main treatment for patients with metastatic cancers. Oligo-progression has become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and resistant clones while receiving systemic therapy. This results in overall tumor response but progression in metastatic sites. Current standard is to change systemic therapies. With advancing technologies, stereotactic body radiation therapy is being used to deliver high doses of focused radiation to the disease site, while minimizing risk of injury to the surrounding organs. SBRT is increasingly being used in patients presenting oligo-metastatic disease, and is recognized as having a potential for cure. This study will investigate the use of SBRT for breast and genito-urinary cancer patients with oligo-progression. Patients will be seen before and at the end of treatment and will be followed at 4 month intervals for up to 2 years. During the visits participants will complete quality of life questionnaires and will have standard of care imaging. Patients will also have the option to provide blood at baseline, during treatment, and at various follow up time points for analysis of ctDNA
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Cancer Centre — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Stereotactic Body Radiotherapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Princess Margaret Cancer Centre — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignancy
- Off-Label Treatment With Immune Checkpoint Inhibitor Blockade — Milwaukee, Wisconsin
- Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects — Anchorage, Alaska
- BostonGene-Integrated Genomic Registry (BIGR) — Waltham, Massachusetts
- Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository — Boston, Massachusetts
Explore by condition: All Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.